MyCancerGene App for Cancer Genetic Testing Outcomes
(MyCancerGene Trial)

Recruiting in Palo Alto (17 mi)

Overseen byAngela Bradbury, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Abramson Cancer Center of the University of Pennsylvania

No Placebo Group

Trial Summary

What is the purpose of this trial?

This protocol aims to evaluate the efficacy of a theoretically and stakeholder informed patient-centered genetic Interactive Health Communication Application to increase patient understanding of, and affective and behavioral responses to genetic testing. The study investigators hypothesize that the intervention will be associated with increases in knowledge, decreases in distress, increases in communication with relatives and health care providers, and increases in performance of risk reducing health behaviors.

Research Team

Angela Bradbury, MD

Principal Investigator

University of Pennsylvania

Eligibility Criteria

This trial is for men and women over 18 who have had genetic counseling and testing for hereditary cancer syndromes within the last 60 days. Participants must speak English and have access to the internet or a mobile device.

Inclusion Criteria

I am either male or female.

Internet and/or mobile access

I am 18 years old or older.

See 2 more

Exclusion Criteria

No internet and/or mobile access

Treatment Details

Interventions

MyCancerGene (Interactive Health Communication Application)

Trial OverviewThe trial is testing 'MyCancerGene,' an interactive health application designed to improve patient understanding of genetic testing results, reduce distress, encourage communication with family and healthcare providers, and promote risk-reducing behaviors.

Participant Groups

2Treatment groups

Experimental Treatment

Active Control

Group I: Intervention GroupExperimental Treatment1 Intervention

Individuals randomized to this arm will receive immediate access to the Interactive Health Communication Application.

Group II: Usual Care GroupActive Control1 Intervention

Individuals randomized to this arm will receive the standard clinical practice.